Oncogene/NN
amplification/NN
correlates/VBZ
with/IN
dense/JJ
lymphocyte/NN
infiltration/NN
in/IN
human/JJ
breast/NN
cancers/NNS
:/:
a/DT
role/NN
for/IN
hematopoietic/JJ
growth/NN
factor/NN
release/NN
by/IN
tumor/NN
cells/NNS
?/.

One/CD
hundred/CD
six/CD
primary/JJ
breast/NN
cancer/NN
samples/NNS
were/VBD
analysed/VBN
for/IN
c-erbB2/NN
,/,
int-2/NN
,/,
and/CC
c-myc/NN
gene/NN
amplification/NN
./.
=====
Surgically/RB
confirmed/VBN
nodal/JJ
involvement/NN
was/VBD
observed/VBN
in/IN
42/CD
%/NN
./.
=====
Level/NN
of/IN
gene/NN
amplification/NN
was/VBD
studied/VBN
by/IN
Southern/NN
and/or/CC
slot/NN
blot/NN
techniques/NNS
./.
=====
Amplified/VBN
c-erbB2/NN
gene/NN
sequences/NNS
were/VBD
present/JJ
in/IN
21.5/CD
%/NN
of/IN
all/DT
samples/NNS
./.
=====
Int-2/NN
was/VBD
amplified/VBN
in/IN
13.1/CD
%/NN
and/CC
c-myc/NN
was/VBD
amplified/VBN
in/IN
10.3/CD
%/NN
./.
=====
In/IN
a/DT
non-parametric/JJ
test/NN
(/(
Kruskal-Wallis/NN
)/)
a/DT
strong/JJ
negative/JJ
association/NN
was/VBD
found/VBN
between/IN
high/JJ
levels/NNS
of/IN
c-erbB2/NN
amplification/NN
and/CC
absence/NN
of/IN
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
(/(
P/NN
=/JJ
.0009/CD
)/)
or/CC
progesterone/NN
receptor/NN
(/(
PR/NN
)/)
(/(
P/NN
=/JJ
.011/CD
)/)
expression/NN
./.
=====
No/DT
correlations/NNS
were/VBD
found/VBN
between/IN
all/DT
or/CC
high/JJ
levels/NNS
of/IN
amplification/NN
of/IN
each/DT
oncogene/NN
separately/RB
or/CC
combined/VBN
with/IN
T/NN
,/,
N/NN
,/,
grade/NN
,/,
multifocality/NN
of/IN
tumor/NN
,/,
or/CC
associated/VBN
carcinoma/NN
in/FW
situ/FW
./.
=====
There/EX
was/VBD
a/DT
trend/NN
approaching/VBG
statistical/JJ
significance/NN
for/IN
patients/NNS
with/IN
c-erbB2/NN
amplifications/NNS
to/TO
have/VB
positive/JJ
lymph/NN
nodes/NNS
at/IN
surgery/NN
(/(
P/NN
=/JJ
0.09/CD
)/)
./.
=====
A/DT
somewhat/RB
surprising/JJ
finding/NN
however/RB
was/VBD
a/DT
very/RB
strong/JJ
association/NN
between/IN
oncogene/NN
amplification/NN
and/CC
dense/JJ
lymphocyte/NN
infiltration/NN
of/IN
the/DT
tumor/NN
(/(
P/NN
=/JJ
.05/CD
)/)
./.
This/DT
correlation/NN
is/VBZ
even/RB
stronger/JJR
when/WRB
only/RB
high/JJ
levels/NNS
of/IN
amplification/NN
are/VBP
considered/VBN
,/,
either/CC
for/IN
each/DT
oncogene/NN
separately/RB
(/(
P/NN
=/JJ
.0048/CD
)/)
or/CC
in/IN
combination/NN
(/(
P/NN
=/JJ
.0007/CD
)/)
./.
=====
We/PRP
propose/VBP
that/IN
malignant/JJ
cell/NN
cytokine/NN
production/NN
may/MD
help/VB
explain/VB
this/DT
observation/NN
./.